Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LEXINGTON, Mass., April 5, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 8,550 shares of Curis common stock to a new employee, with a grant date of April 1, 2024 (the "Q2 2024 Inducement Grant").
馬薩諸塞州列剋星敦，2024 年 4 月 5 日/PRNewswire/--專注於開發治療癌症的創新療法的生物技術公司Curis, Inc.（納斯達克股票代碼：CRIS）今天宣佈，2024 年 4 月 1 日，Curis 董事會獨立薪酬委員會批准向新員工授予總計 8,550 股 Curis 普通股的激勵性股票期權，授予日期爲 2024 年 4 月 1 日（“2024 年第二季度”）激勵補助金”）。
The Q2 2024 Inducement Grant has an exercise price per share equal to the closing price of the Company's common stock on April 1, 2024. The stock option has a 10 year term and vests over four years, with 25% of the original number of shares underlying the award vesting on the first anniversary of the employee's date of hire and an additional 6.25% of the original number of shares underlying the award vesting on each successive three-month period thereafter, subject to the employee's continued service with the Company through the respective vesting dates. The stock option was granted as an inducement equity award outside of the Company's Fourth Amended and Restated 2010 Stock Incentive Plan and was made as an inducement material to the employee's acceptance of employment with the Company.
2024年第二季度激勵補助金的每股行使價等於2024年4月1日公司普通股的收盤價。該股票期權的期限爲10年，在四年內歸屬，該獎勵所依據的原始股份數量的25％在員工受聘之日一週年之際歸屬，此後每連續三個月將獎勵所依據的股票數量的6.25％歸屬，前提是員工在相應的歸屬日期之前繼續在公司任職。該股票期權是在公司第四次修訂和重述的2010年股票激勵計劃之外作爲激勵性股權獎勵授予的，是作爲激勵員工接受公司工作的激勵材料而授予的。
About Curis, Inc.
關於 Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), both of which have received Orphan Drug Designation from the U.S. Food and Drug Administration. Emavusertib is also being evaluated as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge to Genentech, a member of the Roche Group, under which they are commercializing Erivedge for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.
Curis 是一家生物技術公司，專注於開發 emavusertib，這是一種口服可口服的小分子 IRAK4 抑制劑。Emavusertib目前正在與BTK抑制劑依魯替尼聯合對復發/難治性原發性中樞神經系統淋巴瘤（PCNSL）患者進行1/2期TakeAIM淋巴瘤研究的單一療法，進行鍼對復發/難治性急性髓系白血病（AML）和復發/難治性高發性白血病（AML）患者的1/2期TakeAIM白血病研究中的單一療法風險骨髓增生異常綜合徵（HRMD），兩者均已獲得美國食品藥品監督管理局頒發的孤兒藥稱號。在急性髓細胞白血病專利中，Emavusertib還被評估爲阿扎胞苷和venetoclax的一線聯合療法。通過在2015年與Aurigene的合作，Curis獲得了emavusertib（CA-4948）的獨家許可。Curis將其對Erivedge的權利許可給了羅氏集團的成員基因泰克，根據該公司，他們正在將用於晚期基底細胞癌治療的Erivedge商業化。欲了解更多信息，請訪問 Curis 的網站 www.curis.com。
SOURCE Curis, Inc.
來源 Curis, Inc.
譯文內容由第三人軟體翻譯。